Evaluation of off-label rapamycin use on oral health
GeroScience · 06.06.2024 · 46 (5) · 4135-4146
DOI: 10.1007/s11357-024-01221-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift GeroScience, online erschienen am 06.06.2024. Verfasst von Johnny Hudson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Health Sciences, University of Washington, Seattle, WA, 98195, USA. Hauptthemen laut MEDLINE: Off-Label Use, Oral Health, Sirolimus. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Norn Group.
Themen: Mundpflege
Abstract (Originalsprache)
Rapamycin (sirolimus) is an FDA approved drug with immune modulating properties that is being prescribed off-label in adults as a preventative therapy to maintain healthspan. We recently published one of the first reports on 333 adults with a history of off-label rapamycin use. Along with presenting evidence that rapamycin can be used safely in adults of normal health status, we discovered that about 26% of rapamycin users also reported oral health changes. Given the recent evidence highlighting the potential benefits of rapamycin and its derivatives in enhancing oral health, we conducted a secondary data analysis to profile the oral health of off-label rapamycin users, the true incidence of mouth sores, and present specific case studies of periodontal bone loss quantification using an FDA-approved artificial intelligence platform. Contrary to expected findings and previous literature, dimensions of rapamycin usage (such as length of use, dosage, and interval) were not found to be related to the incidence of mouth ulcers in rapamycin users. Notably, among rapamycin users, the most deleterious forms of ulcers were found to be infrequent and not statistically linked to rapamycin usage, with most rapamycin users having a common transient form of mouth ulcers. Additionally, we describe the general oral health outcomes of off-label rapamycin users and provide recommendations for individuals engaging in off-label rapamycin to be regularly checked by a dentist or an oral health care provider. This report was limited by being a secondary data analysis taken from survey data that focused on a more holistic health model. Future studies will use a focused survey that collects data on more dimensions of oral health outcomes while including questions on oral health for non-rapamycin-using participants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Health Sciences, University of Washington, Seattle, WA, 98195, USA.
- Overjet Inc, Boston, MA, 02109, USA.
- Ageless Rx, Ann Arbor, MI, USA.
- Optispan Geroscience, Seattle, WA, 98168, USA.
- Department of Oral Health Sciences, University of Washington, Seattle, WA, 98195, USA. joyan@uw.edu.
ORCID-Profile: Matt Kaeberlein, Jonathan Y An
Förderung
- Norn Group
Zitieren
APA
Hudson, J., Kaeberlein, T., Mahal, A., Wong, N., Ghorbanifarajzadeh, M., Radella, F., Isman, A., Nyquist, A., Zalzala, S., Haddad, G., Kaeberlein, M., & An, J. Y. (2024). Evaluation of off-label rapamycin use on oral health. GeroScience, 46(5), 4135-4146. https://doi.org/10.1007/s11357-024-01221-0
Vancouver
Hudson J, Kaeberlein T, Mahal A, Wong N, Ghorbanifarajzadeh M, Radella F, et al. Evaluation of off-label rapamycin use on oral health. GeroScience. 2024;46(5):4135-4146. doi:10.1007/s11357-024-01221-0
BibTeX
@article{Hudson2024,
author = {Hudson, Johnny and Kaeberlein, Tammi and Mahal, Akashdeep and Wong, Nelson and Ghorbanifarajzadeh, Mina and Radella, Frank and Isman, Anar and Nyquist, Andy and Zalzala, Sajad and Haddad, George and Kaeberlein, Matt and An, Jonathan Y},
title = {Evaluation of off-label rapamycin use on oral health},
journal = {GeroScience},
year = {2024},
volume = {46},
number = {5},
pages = {4135--4146},
doi = {10.1007/s11357-024-01221-0}
}
EUVIMED